The rebrand is the visible part. The real work is turning three separate operations into one measurable growth system — and doing it before the pixels forget what they knew.
You aren't launching a new business. You're clarifying one you already run. Cell Thesis isn't a paint job on Manhattan Laser — it's the argument for why three surfaces belong under one roof.
The pixels, ad accounts, and reviews already have equity. Migrated correctly, they compound. Migrated hastily, you start from zero on all three.
Your first ninety days aren't a launch — they're a measurement build. The ROI dashboard, GHL activation, and lifecycle engine you named are the three legs. We sequence them so nothing falls over.
Longevity buyers behave differently than laser buyers. Higher intent, longer consideration, higher LTV. The consolidation lets you monetize both without cannibalizing.
Recommendation: Growth System ★ — one strategist, an AI-monitored dashboard, paid acquisition, and the migration playbook. The tier is priced for scoping; we hold that number for the call.
The clarifying question isn't what to call the new brand. It's which parts of the old operation were carrying weight — the location count, the founder credibility, the treatment mix, the review stack — and which parts were quietly duplicating themselves across three domains, three inboxes, and three receipts.
Cell Thesis is the name for what happens when you stop paying for three of everything. One booking funnel, one lifecycle engine, one measurement layer, one brand — with three doors that route the same patient into the same care journey. The rebrand is downstream of that decision. Not the other way around.
Two things go from asset to liability the moment the domain flips: the pixels (Meta, Google, and any warmed CAPI audience segments that live under Manhattan Laser's Business Manager), and the reviews (three separate Google Business Profiles carrying the goodwill of two years of care). Both are recoverable. Neither is automatic. Either can be silently vaporized by a fast domain redirect and a slow ad-account migration.
That's the actual work of the first ninety days. Not the launch. The preservation.
| Axis | Today · Three clinics | Ninety days · Cell Thesis |
|---|---|---|
| Brand identity | Manhattan Laser — three URLs, three Google Business Profiles, one Instagram doing the work of all three. | Cell Thesis — one brand register that reads longevity + aesthetics, three location pages that all inherit the same authority. |
| Attribution | Bookings live in GHL. Ad spend lives in Meta. Nothing joins them without hand-matching phone numbers. | One dashboard. Ad → click → session → booking → shown → treatment cycle → LTV. Named source per booking, per location. |
| Pixel & audience assets | Meta pixel warmed under manhattan-laser.com. Roughly 24 months of visit and event history. At risk in a domain flip. | Pixel re-parented to cellthesis.com without losing the event history. Custom audiences preserved; new source labels appended, not replaced. |
| Reviews | Three GBPs at 4-star tiers. Two years of patient reviews you own but can't merge. Bay Ridge is quietly leading; Midtown is quietly lagging. | Three GBPs re-labeled to Cell Thesis. Review-request automation firing at the "shown + billed" event. Consistent monthly volume across all three doors. |
| Paid acquisition | Meta running. Google mostly dormant. LSA/Local Services Ads absent. Retargeting light. | Meta continues at scale under new identity. Google Search + LSA + Performance Max covering local intent. Retargeting keyed to booking-funnel stage. |
| Lifecycle & retention | One-off email blasts. No treatment-cycle flow. No membership monetization on injectables cadence. | Welcome flow, treatment-cycle replenishment flow, lapsed-patient reactivation. Optional membership tier layered on high-frequency treatments. |
| Positioning | "Aging gracefully is overrated." Anti-aging tilt within med-aesthetics. Sits alongside every other NYC med spa. | Cellular · Preventive · Performance. Longevity register at the front, aesthetics as the treatment expression. Fewer competitors at the top of the funnel. |
| Operator visibility | Roman leads the team page. Founder story present but not paid-forward as authority. | Founder-led authority content (short-form, one channel at a time). Longevity/aesthetics thesis in the operator's own voice. |
You already named the shape of the first ninety days in your reply. This is our reading of what "done" looks like on each — and why they have to sequence in this order.
One live view that shows, per location, per channel: spend, sessions, booked consults, shown consults, treatments performed, revenue, and gross margin. Not five dashboards. One. Warehoused in the tool you already trust, refreshed daily, with an anomaly detector on the top three metrics.
Migrate — don't rebuild — the Meta and Google pixels, custom audiences, and event history from manhattan-laser.com to cellthesis.com. Re-attribute conversions cleanly. Preserve the twenty-four months of learning; append the new brand identity instead of overwriting it.
The three flows that turn a first laser booking into a treatment cycle, a treatment cycle into a membership, and a lapsed patient back into a shown consult. Built in your GHL instance, keyed to real events (booked / shown / treated / lapsed), with founder-voice copy that reads like Cell Thesis — not template.
Priority I answers the question "is this working?" — you cannot pressure-test priorities II and III without it. Priority II answers "did we bring the audience with us?" — you cannot scale under the new brand without it. Priority III answers "do our patients come back?" — the LTV question that governs the whole model.
The consolidation only works if the buyer segmentation is honest. These are the three actual patients — different acquisition costs, different lifetime values, different sequences.
Late 20s to early 40s, NYC-local, price-sensitive on the first visit, browses via Instagram and Google Maps, books via the promo pill on the site or a Meta ad. First-treatment CAC is real; the whole model depends on the second visit.
Mid-30s to mid-50s, higher AOV, treatment cycles run at natural biological cadence (roughly quarterly on toxins, semi-annual on fillers). Books directly, reschedules on-site, opens SMS, opens email. Where the practice compounds. Most under-monetized: no membership, no cycle-based reminder economics.
35-plus, higher household income, walking in via wellness & longevity — bloodwork, IV drip, peptide, hormone, PRP hair, biological-age testing if you offer it. Higher intent, longer consideration, LTV several multiples above the laser first-timer. Reads before booking. Wants a founder voice.
AYMI runs every engagement through the same five steps. On a consolidation like Cell Thesis, the steps look like this:
Audit the three existing surfaces, the current pixel state, the GBP inventory, the review stack, and the historic ad performance. Interview the team on the friction they see.
Sequence the migration. Choose which channels lead. Define target CPAs per persona and per location. Lock the dashboard schema.
Build the launch assets in the Cell Thesis register: Meta creative for each persona, founder-led long-form for the longevity buyer, GBP media refresh.
Coordinated same-day: pixel migration, domain flip, GBP updates, ad-account rename, welcome flow arm. Nothing dark for more than an hour.
Weekly performance rhythm. Monthly strategy review. Anomaly alerts on the dashboard. Quarterly cadence for the founder-authority pipeline.
You're already running Meta. That's the good news and the risk. Live paid delivery is your best pixel data, and it's also what gets casually erased in a "let's just start fresh under the new brand" moment.
Local intent for laser, injectables, and wellness in NYC is enormous, and largely uncaptured on your side of the ledger. The three Google Business Profiles are the biggest under-monetized asset in the current stack.
Manhattan Laser could only talk about aesthetics. Cell Thesis can talk about cellular health, prevention, performance, hormone optimization, sleep, recovery — the full frame that patient III is actually shopping for. That's a content unlock, not a color palette unlock.
Aesthetics done well is the replenishment business. Toxins cycle. Fillers cycle. Laser hair removal courses. IV drips renew. What Manhattan Laser doesn't have — a lifecycle engine — is exactly what turns the three locations into a compounding book. Priority III in your reply is our priority III in the build.
Every dollar of Meta and Google is judged at the moment a patient chooses to click "book." A four-percent lift in booking-page conversion is worth more than a four-percent drop in CPC. That's the whole game on paid.
You called it "target growth ROI metrics + workflows." We call it "the one view that lets you fire an underperforming channel with confidence." Same idea. Everything else in the engagement is judged against what this dashboard reports.
This is the single riskiest technical maneuver of the launch and, done properly, one of the cleanest wins available. The Meta and Google pixels have been collecting event data under manhattan-laser.com for two years. That data is portable — but only if the migration is scripted, not improvised.
Nothing in this section is "creative work." All of it is technical hygiene that separates a rebrand that keeps its audience from a rebrand that starts over. The cost of doing it right is small. The cost of doing it wrong is the entire twenty-four months.
These are the three shapes an AYMI engagement can take for Cell Thesis. The investment for each is held for the scoping call — we'd rather decide together what's in scope first, then price it once the answer is real.
| Shape | Team | AI Dashboard | Best fit |
|---|---|---|---|
| Foundation | 1 strategist | — | You want the migration executed cleanly and lifecycle running, but you'll own paid + Google in-house. |
| ★ RECOMMENDEDGrowth System | 1 strategist + paid lead | Included | You want the migration, the dashboard, paid acquisition (Meta + Google + LSA), and the lifecycle engine, all run as one system. |
| Full Longevity OS | 2 strategists + creative lead + paid lead | Included, plus founder-authority pipeline | You want the above plus a founder-content engine (Roman as the operator voice for longevity) and the runway to build the membership + IV/hormone/regen expansion as a full growth org. |
These are AYMI case studies chosen for structural fit — multi-location acquisition, subscription lifecycle, and specialty patient economics.
Why this maps: multi-state, multi-location behavioral-health platform running a rebrand-adjacent acquisition system. Closest structural match to a three-clinic roll-up under one brand.
Why this maps: the operating answer to "how does the next chair fill?" — provider-matching engine across specialty SEO + content + intent paid. Directly applicable to filling the three location schedules under Cell Thesis.
Why this maps: cycle-based replenishment economics, practitioner-endorsed authority, and the LTV thesis that governs any aesthetics or longevity treatment cadence. The Priority III blueprint.
The Foundation tier could technically deliver the migration cleanly. But once the pixels are re-parented, the immediate next question — "what should we do with all this preserved audience?" — needs paid muscle that Foundation doesn't include. Waiting a quarter to add paid is a quarter of the compounding you'd otherwise get.
The Full Longevity OS is right if you want to build a founder-authority pipeline in Roman's voice from day one — a serious lever for the highest-LTV persona — and if the membership + IV/hormone/regen expansion is already scoped. If those are Q2 questions, not Q1 questions, Full Longevity OS is early.
Growth System ★ is the shape that matches your three named priorities and the timing of the rebrand. It ships the migration, the dashboard, paid acquisition across Meta + Google + LSA, and the lifecycle engine in the same ninety days — the sequencing the anchor recommendation lays out. It's the smallest engagement that answers all three of your priorities cleanly.
The investment sits in the middle of the ladder. It's held for the scoping call.
The rebrand from Manhattan Laser to Cell Thesis is the single largest surface change your practice will make in the next five years. It's also the single largest opportunity — if the migration runs cleanly and the measurement layer arrives on the same day. Talk in the next few days.
Book the scoping call →